9/23
08:07 am
prld
Prelude Therapeutics (NASDAQ:PRLD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
High
Report
Prelude Therapeutics (NASDAQ:PRLD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.